We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tocilizumab administration in patients with SARS‐CoV‐2 infection: Subcutaneous injection vs intravenous infusion.
- Authors
Shabani, Minoosh; Shokouhi, Shervin; Moradi, Omid; Saffaei, Ali; Sahraei, Zahra
- Abstract
Keywords: COVID-19; Cytokine storm syndrome; Pharmacokinetic; Tocilizumab EN COVID-19 Cytokine storm syndrome Pharmacokinetic Tocilizumab 69 70 2 12/31/20 20210101 NES 210101 Recent studies have revealed that cytokine storm syndrome, which is caused by the activation of inflammatory cytokines, is likely underlying pathophysiology in patients with severe COVID-19 that has been associated with a high mortality rate.1 Interleukin-6 (IL-6) plays a predominant role in this cascade, and tocilizumab (a humanized monoclonal antibody against IL-6 receptors) can interfere with this cascade. This suggests that there may be no need for dose conversion.4 Considering the abovementioned parameters, it can be concluded that the administration of tocilizumab at a dose of 400 mg through the intravenous route (desired dose) may be equivalent to 400 mg tocilizumab through the subcutaneous route, despite the pharmacokinetic differences. They found that the efficacy and safety of subcutaneous tocilizumab at a single dose of 162 mg is comparable with the intravenous route (8 mg/kg with a second dose 12 hours after the first dose and a possible third dose after next 24-36 hours, based on the clinical response).
- Subjects
INTRAVENOUS injections; INTRAVENOUS therapy; SARS-CoV-2; SUBCUTANEOUS injections; TOCILIZUMAB
- Publication
Journal of Medical Virology, 2021, Vol 93, Issue 1, p69
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.26124